Amneal Pharmaceuticals (AMRX) Non-Current Debt (2017 - 2026)

Amneal Pharmaceuticals' Non-Current Debt history runs 10 years deep, the most recent figure standing at $2.6 billion for Q1 2026.

• In Q1 2026, Non-Current Debt rose 19.11% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 19.11% YoY), while the FY2025 annual figure was $2.6 billion, up 18.66% from the prior year.
• Non-Current Debt was $2.6 billion for Q1 2026 at Amneal Pharmaceuticals, roughly flat from $2.6 billion in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $2.6 billion in Q4 2022 to a low of $38.4 million in Q1 2022.
• Historically, Non-Current Debt has averaged $2.0 billion across 5 years, with a median of $2.4 billion in 2024.
• Biggest YoY gain for Non-Current Debt was 6714.19% in 2022; the steepest drop was 98.57% in 2022.
• A 5-year view of Non-Current Debt shows it stood at $2.6 billion in 2022, then retreated by 7.95% to $2.4 billion in 2023, then declined by 9.4% to $2.2 billion in 2024, then increased by 18.66% to $2.6 billion in 2025, then grew by 0.02% to $2.6 billion in 2026.
• The last three Non-Current Debt figures came in at $2.6 billion (Q1 2026), $2.6 billion (Q4 2025), and $2.6 billion (Q3 2025), per Business Quant data.